Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)Zacks Investment Research • 06/14/24
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity DrugThe Motley Fool • 06/14/24
Eli Lilly Runs Up 49% With Expectations For Weight-Loss Sales To TripleInvestors Business Daily • 06/12/24
Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drugCNBC • 06/11/24
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA AnalystBenzinga • 06/11/24
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA WinInvestors Business Daily • 06/11/24
Eli Lilly Stock Hits New 52-Week High as FDA Panel Recommends Alzheimer's DrugInvestorPlace • 06/11/24